Deepbridge Reports Record Year of Funding

25th April 2022

As of the 25th April 2022, Deepbridge Capital is proud to announce that it has deployed a record £31.5 million into early-stage technology and life sciences companies during the 2021/22 tax year, up from £29.4 million in 2020/21.

GenoME Diagnostics Awarded £50K To Aid Early Detection Of Ovarian Cancer

12th March 2022

GenoME Diagnostics, an investee company within Deepbridge's Life Sciences SEIS portfolio has recently won a £50,000 award that is to be given to Shannon Beattie (CEO - GenoME Diagnostics) as part of the celebrations marking International Women’s Day on March 8th 2022, which will be used to aid early detection of ovarian cancer.

FluoretiQ Closes £1.1 Million Funding Round

21st February 2022

 

FluoretiQ, which is part of the Deepbridge Life Sciences EIS portfolio, as of February 21st 2022, has announced the completion of a £1.1 million, pre-series A investment. The funding round was led by Deepbridge Capital, with significant participation from MAINStream, OION, SAIC and existing investors. 

Deepbridge Shortlisted for Deal of the Year Award

7th February 2022

 

Deepbridge Capital has been shortlisted for the Deal of the Year (Transaction size below £2.5 million) Award at the upcoming 2022 Insider Media, Northern Ireland Dealmakers Awards. 

The 2022 Northern Ireland Dealmakers Awards will be honouring the achievements of the highly committed professional corporate finance community, which has supported businesses across Northern Ireland over the last 12 months. 

Glyconics Secures £1.5m Investment

22nd November 2021

Glyconics, which is part of the Deepbridge Life Sciences EIS portfolio, has secured £1.5 million in an Enterprise Investment Scheme (EIS) funding round ahead of a series A round next year. 

Deepbridge Deploys £50M into UK Life Sciences Companies

27th October 2021

Deepbridge Capital has deployed over £50 million of capital into UK life sciences companies.

The Deepbridge Life Sciences EIS was launched in 2017 as our first life sciences focused EIS fund, providing private investors with access to a portfolio of early-stage investee companies across the biopharmaceutical, biotechnology, medical technology and digital healthcare sectors.